Literature DB >> 25138135

A vanishing lymphoma in the cheek.

Douglas Farquhar1, Joseph Sobanko, Kimberly Williams, Jason G Newman.   

Abstract

BACKGROUND: We describe the unusual case of a 66-year-old woman who presented with a cheek mass that completely abated with oral steroids. CASE REPORT: Multiple separate biopsies of the mass were negative or inconclusive. MRI revealed a large mass, yet after a short steroid course, this mass was completely undetectable on clinical examination. A repeat biopsy eventually revealed follicular lymphoma. DISCUSSION: Lymphomas are known to be steroid sensitive; the medication is an essential component of the common CHOP therapy. While known to occur in the central nervous system, to the best of our knowledge, the presence of a 'vanishing' lymphoma has not been documented in the head and neck. We discuss the likely physiology of the vanishing lymphoma, and the diagnostic difficulty it presents.
CONCLUSION: When a lymphoma is suspected, patient care may be optimized if biopsy is delayed until steroids have been discontinued.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25138135     DOI: 10.1159/000365853

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  2 in total

1.  The Vanishing Adrenal Glands: A Transient Regression of Adrenal Lymphoma After a Single Dose of 1 mg Dexamethasone.

Authors:  Shamaila Zaman; Hessa Boharoon; Neelam Khalid; Sasha Marks; Ali Alsafi; Rashpal Flora; Neil Hill; Emma Hatfield; Karim Meeran
Journal:  AACE Clin Case Rep       Date:  2020-12-28

Review 2.  Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature.

Authors:  Maxime Peeters; Joris Geusens; Fréderic Van der Cruyssen; Lucienne Michaux; Laurence de Leval; Thomas Tousseyn; Peter Vandenberghe; Constantinus Politis
Journal:  Pathol Oncol Res       Date:  2021-04-08       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.